Abstract:Background According to prescribing information for Myrtol standardized enteric-coated soft capsules, the medicine should be taken on an empty stomach. Some patients may experience stomach discomfort after oral administration in fasted state and would prefer to take the medicine after a meal. However, there is no literature addressing the effect of meal on absorption of this drug; therefore, it is desirable to explore the feasibility of taking the capsule after a meal from pharmacokinetic perspective. Methods A gas chromatography coupled with triple quadruples mass spectrometry assay was established and validated for determining plasma concentrations of eucalyptol, a target component of Myrtol standardized capsules. A self-control clinical study was carried out in healthy male volunteers in fasted and fed states after a single oral dose of 300 mg capsules. Comparison of pharmacokinetic parameters in the two phases and bioequivalence evaluation were performed. Results The specificity, sensitivity, accuracy, and precision of the assay satisfied the requirements for biopharmaceutical analysis. Pharmacokinetic parameters of eucalyptol (fasted vs fed) were as follows: maximal plasma concentrations (Cmax) (167.60±114.69 vs 518.89±314.47 ng·mL−1), time of maximum concentration (Tmax) (3.7±1.1 vs 4.8±0.7 h), elimination half-life (T1/2) (3.2±1.4 vs 2.6±0.7 h), area under the plasma concentration–time curve (AUC0–t) (584.91±369.90 vs 1,271.61±605.82 ng·h·mL−1), and AUC0–∞ (690.36±467.26 vs 1,458.02±720.21 ng·h·mL−1). There was statistically significant difference in Cmax, AUC0–t, and AUC0–∞ between the two dosing methods (P<0.05). Pharmacokinetic parameters of eucalyptol given in fasted state in Chinese were comparable to those in Germany population. The 90% confidence intervals for the ratio of Cmax (18.4%~64.7%), AUC0–t (28.9%~68.5%), and AUC0–∞ (31.1%~68.4%) values for the test (fasted) and reference (fed) were beyond the Food and Drug Administration’s acceptable range of 80%~125%. In addition, significant difference was obtained in Tmax (P<0.05). Conclusion Compared with dosing at fasted state, taking Myrtol standardized capsules after a meal achieves a delayed absorption rate and an increased absorption extent. The two dosing methods were not bioequivalent in this small study and, thus, not interchangeable. Patient preference and pharmacokinetic food–drug interaction issue should be balanced. Further clinical study is necessary to explore the clinical outcome of oral administration of Myrtol standardized capsules after or with meal.

Effects of high fat and calories diet on pharmacokinetics of melatonin prolonged-release tablet in healthy Chinese subjects

Pharmacokinetics and Safety of Melatonin Prolonged-Release Tablets in Healthy Chinese Subjects

Effect of Food on the Pharmacokinetics of Tenofovir Amibufenamide: A Phase I, Randomized, Open-Label, Two-Period Crossover Trial in Healthy Adult Subjects

Is It Appropriate Regarding Patient Preference to Take Myrtol Standardized Enteric-Coated Soft Capsules after a Meal Rather Than at Fasted State? A Food–drug Pharmacokinetic Interaction Study in Healthy Chinese Volunteers

Effects of High-fat and High-calorie Diets on Pharmacokinetics of Cefuroxime Axetil Tablets

Food Effects on the Human Pharmacokinetics of Rasagiline Mesylate

Preventive and therapeutic effects of melatonin on rat fatty liver induced by high fat feeding

Effect of a high‐fat meal on the relative bioavailability of HMPL‐689 in Chinese Healthy Volunteers

Comparative Pharmacokinetics of Sustained-Release versus Immediate-Release Melatonin Capsules in Fasting Healthy Adults: A Randomized, Open-Label, Cross-Over Study

Development of a sensitive UPLC-MS/MS assay for domperidone and pharmacokinetics of domperidone tablet formulations in fasting and fed Chinese healthy subjects

Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: A meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies

Influence of Administering Food on Pharmacokinetics of Telmisartan Tablet in Healthy Subjects

Effect of melatonin on visceral fat deposition, lipid metabolism and hepatic lipo‐metabolic gene expression in male rats

Pharmacokinetics, safety and bioequivalence of two formulations of progesterone soft capsule in healthy Chinese postmenopausal females: Impacts of a high-fat meal

Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers

EFFECTIVENESS OF MELATONIN AND RESVERATROL COMBINED ADMINISTRATION IN ROUND-THE-CLOCK ILLUMINATION WITH HIGH-CALORIE CARBOHYDRATE-LIPID DIET

Bioequivalence and Pharmacokinetic Profiles of 2 Trimetazidine Modified-release Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects

Effects of Food and Multiple‐dose Administration on the Pharmacokinetic Properties of HR20033, a Sustained‐release Formulation of Henagliflozin and Metformin for the Treatment of Diabetes, in Healthy Chinese Volunteers

The Effects of Food on the Pharmacokinetics of Mitiglinide Tablets in Healthy Volunteers and A Novel Mass-Spectrometric (Uplc-Ms/ms) Method for Such Studies

Melatonin Supplementation and Anthropometric Indices: A Randomized Double-Blind Controlled Clinical Trial

Melatonin reprogramming of gut microbiota improves lipid dysmetabolism in high‐fat diet‐fed mice